The clinical significance of FLT3 ITD mutation on the prognosis of adult acute promyelocytic leukemia

References

• Wang Z-Y, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111(5):2505–2515. doi: 10.1182/blood-2007-07-102798
   PubMed Web of Science ®Google Scholar
• Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100:59–66. doi: 10.1182/blood.V100.1.59
   PubMed Web of Science ®Google Scholar
• Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4):1247–1253.
   PubMed Web of Science ®Google Scholar
• Lengfelder E, Reichert A, Schoch C, et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia. 2000;14:1362–1370. doi: 10.1038/sj.leu.2401843
   PubMed Web of Science ®Google Scholar
• Schnittger S, Weisser M, Schoch C, et al. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood. 2003;102:2746–2755. doi: 10.1182/blood-2003-03-0880
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752–1759. doi: 10.1182/blood.V98.6.1752
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074–3080.
   PubMed Web of Science ®Google Scholar
• Kondo M, Horibe K, Takahashi Y, et al. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med Pediatr Oncol. 1999;33:525–529. doi: 10.1002/(SICI)1096-911X(199912)33:6<525::AID-MPO1>3.0.CO;2-8
   PubMedGoogle Scholar
• Abu-Duhier FM, Goodeve AC, Wilson GA, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol. 2000;111:190–195. doi: 10.1046/j.1365-2141.2000.02317.x
   PubMed Web of Science ®Google Scholar
• Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97:89–94. doi: 10.1182/blood.V97.1.89
   PubMed Web of Science ®Google Scholar
• Beitinjaneh A, Jang S, Roukoz H, et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. Leuk Res. 2010;34:831–836. doi: 10.1016/j.leukres.2010.01.001
   PubMed Web of Science ®Google Scholar
• Minami S, Kuriyama K. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia study group of the ministry of health and welfare (Kohseisho). Leukemia. 1997;11(10):1447–1452.
   PubMedGoogle Scholar
• Noguera NI, Breccia M, Divona M, et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia. 2002;16(11):2185–2189. doi: 10.1038/sj.leu.2402723
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Naoe T, Yokota S, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia study group of the ministry of health and welfare (Kohseisho). Leukemia. 1997;11:1447–1452. doi: 10.1038/sj.leu.2400756
   PubMed Web of Science ®Google Scholar
• Shih L-Y, Kuo M-C, Liang D-C, et al. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer. 2003;98:1206–1216. doi: 10.1002/cncr.11636
   PubMed Web of Science ®Google Scholar
• Au WY, Fung A, Chim CS, et al. FLT-3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact. Br J Haematol. 2004;125:463–469. doi: 10.1111/j.1365-2141.2004.04935.x
   PubMed Web of Science ®Google Scholar
• Molica M, Breccia M. FLT3-ITD in acute promyelocytic leukemia: clinical distinct profile but still controversial prognosis. Leuk Res. 2015;39:397–439. doi: 10.1016/j.leukres.2015.01.004
   PubMed Web of Science ®Google Scholar
• Breccia M, Loglisci G, Loglisci MG, et al. FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis. Haematologica. 2013;98(12):e161–e163. doi: 10.3324/haematol.2013.095380
   PubMed Web of Science ®Google Scholar
• Li W, Zhang L, Huang L, et al. Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML. Leuk Res. 2012;36:186–191. doi: 10.1016/j.leukres.2011.08.014
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Green C, et al. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood. 2010;115:948–956. doi: 10.1182/blood-2009-08-236588
   PubMed Web of Science ®Google Scholar
• Callens C, Chevret S, Cayuela J-M, et al. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia. 2005;19:1153–1160. doi: 10.1038/sj.leu.2403790
   PubMed Web of Science ®Google Scholar
• Souza Melo CP, Campos B, Dutra ÁP, et al. Correlation between FLT3–ITD status and clinical, cellular and molecular profiles in promyelocytic acute leukemias. Leuk Res. 2015;39:131–137. doi: 10.1016/j.leukres.2014.11.010
   PubMed Web of Science ®Google Scholar
• Barragán E, Montesinos P, Camos M, et al. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica. 2011;96(10):1470–1477. doi: 10.3324/haematol.2011.044933
   PubMed Web of Science ®Google Scholar
• Kuchenbauer F, Schoch C, Kern W, et al. Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia. Br J Haematol. 2005;130:196–202. doi: 10.1111/j.1365-2141.2005.05595.x
   PubMed Web of Science ®Google Scholar
• Iland H, Bradstock K, Seymour J, et al. Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica. 2012;97(2):227–234. doi: 10.3324/haematol.2011.047506
   PubMed Web of Science ®Google Scholar
• Singh H, Werner L, DeAngelo D, et al. Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations. Am J Hematol. 2010;85(12):956–957. doi: 10.1002/ajh.21867
   PubMed Web of Science ®Google Scholar
• Hu J, Liu Y-F, Wu C-F, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci. 2009;106(9):3342–3347. doi: 10.1073/pnas.0813280106
   PubMed Web of Science ®Google Scholar
• Gale RE, Hills R, Pizzey AR, et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood. 2005;106:3768–3776. doi: 10.1182/blood-2005-04-1746
   PubMed Web of Science ®Google Scholar
• Hong S-D, Kim Y-K, Kim H-N, et al. Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3 /ITD mutation in acute promyelocytic leukemia patients. Korean J Hematol. 2011;46:24–30. doi: 10.5045/kjh.2011.46.1.24
   PubMedGoogle Scholar
• Schnittger S, Bacher U, Haferlach C, et al. Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA. Haematologica. 2011;96(12):1799–1807. doi: 10.3324/haematol.2011.049007
   PubMed Web of Science ®Google Scholar
• Poiré X, Moser BK, Gallagher RE, et al. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma. 2014;55(7):1523–1532. doi: 10.3109/10428194.2013.842985
   PubMed Web of Science ®Google Scholar
• Song X, Hu X, Lu S, et al. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia. Eur J Haematol. 2014;93:54–62. doi: 10.1111/ejh.12301
   PubMed Web of Science ®Google Scholar
• Shen Y, Fu Y-K, Zhu Y-M, et al. Mutations of epigenetic modifier genes as a poor prognostic factor in acute promyelocytic leukemia under treatment with all-trans retinoic acid and arsenic trioxide. EBioMedicine. 2015;2:563–571. doi: 10.1016/j.ebiom.2015.04.006
   PubMed Web of Science ®Google Scholar
• Lou Y, Ma Y, Suo S, et al. Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy. Leuk Res. 2015;39:938–944. doi: 10.1016/j.leukres.2015.05.016
   PubMed Web of Science ®Google Scholar